Sinopharm Group Co. Ltd. (OTCMKTS:SHTDY – Get Free Report) saw a significant drop in short interest in May. As of May 15th, there was short interest totaling 11,536 shares, a drop of 72.8% from the April 30th total of 42,380 shares. Based on an average daily trading volume, of 163,961 shares, the short-interest ratio is currently 0.1 days.
Sinopharm Group Stock Down 0.7%
Sinopharm Group stock traded down $0.08 during midday trading on Friday, reaching $10.73. The company’s stock had a trading volume of 133,219 shares, compared to its average volume of 63,059. Sinopharm Group has a fifty-two week low of $10.57 and a fifty-two week high of $14.87. The business has a 50-day simple moving average of $12.32 and a 200-day simple moving average of $12.89.
About Sinopharm Group
Sinopharm Group Co, Ltd. (OTCMKTS:SHTDY) is one of China’s largest integrated healthcare companies and an indirect subsidiary of the state-owned China National Pharmaceutical Group Co, Ltd. The company operates through two primary segments—pharmaceutical distribution and retail pharmacy—offering comprehensive supply chain solutions that span procurement, storage, transportation and sales of medical products. With a broad portfolio that includes prescription drugs, over-the counter medicines, medical devices and consumables, Sinopharm serves hospitals, clinics, retail pharmacies and other healthcare institutions across mainland China.
In its distribution business, Sinopharm leverages an extensive logistics network, comprising hundreds of distribution centers and thousands of delivery vehicles, to ensure timely delivery of pharmaceuticals under stringent temperature-controlled conditions.
Read More
- Five stocks we like better than Sinopharm Group
- These 3 CLO ETFs Target a Niche Corner of the Fixed-Income Market
- 3 Ways to Play the Data Center Land Grab
- The Smarter Way to Invest in AI Without Taking Extreme Risk
- 3 Dividend Kings That Earn Their Crown Every Quarter
Receive News & Ratings for Sinopharm Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinopharm Group and related companies with MarketBeat.com's FREE daily email newsletter.
